SCM
FATE icon

Soleus Capital Management’s Fate Therapeutics FATE Stock Holding History

Soleus Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-870,000
Closed -$2.85M – 91
2024
Q2 		$2.85M Hold
870,000
– – 0.25% 73
2024
Q1 		$6.39M Buy
+870,000
New +$5.39M 0.47% 58
2022
Q4 		– Sell
-67,300
Closed -$1.51M – 78
2022
Q3 		$1.51M Sell
67,300
-127,100
-65% -$3.67M 0.2% 62
2022
Q2 		$4.82M Sell
194,400
-11,500
-6% -$317K 0.75% 40
2022
Q1 		$7.98M Buy
205,900
+198,100
+2,540% +$7.67M 1.03% 32
2021
Q4 		$456K Buy
+7,800
New +$442K 0.05% 64
2021
Q1 		– Sell
-6,830
Closed -$621K – 77
2020
Q4 		$621K Sell
6,830
-2,882
-30% -$179K 0.08% 60
2020
Q3 		$388K Sell
9,712
-23,288
-71% -$813K 0.21% 57
2020
Q2 		$1.13M Buy
+33,000
New +$984K 0.65% 37
2020
Q1 		– Sell
-11,400
Closed -$223K – 53
2019
Q4 		$223K Buy
+11,400
New +$181K 0.22% 48

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Soleus Capital Management's FATE Position: Q3 2024 in Review

Soleus Capital Management sold out of Fate Therapeutics (FATE) in Q3 2024, closing a stake of 870,000 shares — an estimated $2.85M sold.

Soleus Capital Management first reported a position in FATE in Q4 2019 and held it in 10 quarters. The position peaked at $7.98M in Q1 2022. 164 funds tracked by Wall St. Rank hold FATE as of Q3 2024.

  • Soleus Capital Management reported no remaining Fate Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Soleus Capital Management sold 870,000 Fate Therapeutics shares in Q3 2024, an estimated $2.85M.
  • Soleus Capital Management first reported a position in Fate Therapeutics in Q4 2019 and held it in 10 quarters.
  • Soleus Capital Management's Fate Therapeutics position peaked at $7.98M in Q1 2022.
  • 164 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2024.

Based on Soleus Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.